Active secondary progressive MS is defined as people experiencing relapses or showing signs of inflammation in MRI scans
This is exciting news, as siponimod is the first oral drug to be licensed for secondary progressive MS in Europe. Secondary progressive MS has an impact on all aspects of people’s lives – physical, emotional, social and economic - affecting not only the person diagnosed, but also their families. We hope that the availability of a new treatment will lead to a renewed focus on the needs of all people with progressive MS and improve their access to services.
- David Martin, Chief Executive Officer, MS Trust
As someone with SPMS I am delighted that at last a treatment has been licensed for people like myself. For too long we have been excluded from services and been ignored, this decision provides an opportunity to slow our disease progression with the possibility of improving our quality of life immeasurably. Roll on NICE approval.
- Caroline Smith
The next step in the approval process is for the European Commission to grant the licence, taking into the consideration the EMA's recommendation. Siponimod will then be appraised by NICE and SMC to decide whether it is a cost-effective treatment for the NHS.
NICE has already started the appraisal process for siponimod and a decision is expected in May 2020. The MS Trust is responded to the appraisal. If NICE approves the use of siponimod, it could be available on the NHS by the end of 2020.
Siponimod is taken as a tablet, once a day.
In clinical trials for secondary progressive MS, siponimod reduced the risk of disability progression by 26% compared to placebo. Further analysis indicated a 37% reduction in the risk of progression for those with active SPMS (defined as those who had relapsed in the two years prior to starting the trial).
In clinical trials, low white blood cell count, increased liver enzyme levels, slower heart rate when starting treatment, macular oedema (swelling in the back of the eye affecting vision), high blood pressure, shingles, and convulsions occurred more frequently with siponimod than with placebo.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 Jul 2021 - 00:00
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Stem cell transplants in the news
5 Jul 2021 - 00:00
Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.
MS onset in childhood: do disease modifying drugs delay long term disability?
17 Jun 2021 - 00:00
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
With a little help from my furry friend
21 Jul 2021 - 00:00
Lisa, who was diagnosed with MS in 2008 tells us about how creativity and a little help from Spud the hamster helped her get through tougher times.
People with MS thoughts on freedom day
19 Jul 2021 - 00:00
From Monday the 19th of July, most covid restrictions have been lifted in England but what are people with MS really feeling about the so called "Freedom day"?
In this article we talk to some people with MS about their feelings, plus we cover what you can do if you are worried about the lifting of restrictions.
Just keep wheeling
14 Jul 2021 - 00:00
Emily, also known as The Wibbly Dinosaur, discusses her feelings on mobility aids and how using a wheelchair provides her with the freedom to continue doing the things she enjoys.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.